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Coronavirus Disease 2019: The pivotal role of UK Clinical Oncology 
and the UK Coronavirus Cancer Monitoring Project 
The United Kingdom (UK) is currently in the middle of the COVID-19 pandemic. The 
causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel 
strain of coronavirus previously unidentified in humans and thought to be of zoonotic origin 
(1). SARS-COV-2 exposure may result in a wide variety of outcomes, ranging from 
asymptomatic infection to the development of respiratory failure requiring ventilatory support 
(2). COVID-19 is extremely contagious and as of 6th May 2020, there were over 200,000 
cases and 30,000 deaths reported in the UK alone (3,4).  
Globally there has been huge disruption to everyday life. Without a vaccine or effective 
treatment, governments are reliant upon strategies such as social distancing and quarantine 
measures to limit SARS-CoV-2 infection to a level which can be managed by healthcare 
systems (5). Furthermore, the additional burden placed on healthcare services is likely to 
impact the quality of care for patients suffering with unrelated health problems. This is of 
particular relevance to oncologists as prompt diagnosis and treatment can make significant 
difference to patient outcomes. In addition, individuals with a significant co-morbidity such as 
cancer may be particularly vulnerable to coronavirus infection as a potential consequence of 
their immunosuppressed state (6–8).  
This leaves us as oncologists faced with challenging decisions about how to proceed with 
treatment for patients with cancer. The risks of COVID-19 infection have to be incorporated 
into our decision making and will impact on our practice for months or potentially years to 
come. This has led to the need to have difficult conversations with patients about how the 
COVID-19 pandemic affects their treatment, with realistic weighing up of the potential 
benefits and harms that can occur. In our experience, most patients have been remarkably 
pragmatic about the current situation and the measures we are putting in place, but this is an 
emotive area and conversations about stopping or delaying treatment are difficult. To 
effectively and compassionately have these conversations we need to be informed by the 
best evidence available and at present this is limited. Much of the current published literature 
around COVID-19 and cancer is guidelines and the published studies we have are largely 
based around smaller numbers of patients in the Chinese population. 
Despite the uncertainty about which treatments are safe to continue and the full extent of the 
risks from the COVID-19 pandemic significant changes to the delivery of cancer services 
have already been made. With the limitations on hospital resources meaning the usual 
support to manage anticancer treatment toxicities are potentially reduced or unavailable and 
with the additional risk to patients with cancer who contract a concurrent COVID-19 infection 
(7,8), oncological treatments which may confer an unacceptable risk as perceived by 
patients and clinicians are being altered, cancelled or deferred. Guidance has been 
produced as to how to best balance the risks of treating against the risks of changing away 
from the standard treatment, such as the Royal College of Radiologist (RCR) guidelines for 
radiotherapy during the Covid-19 pandemic (9,10).  
Pragmatically in the absence of a definite understanding of how COVID-19 will impact 
patients with cancer the key approach has been to minimise the chance of the patient 
contracting COVID-19 infection. A number of strategies have already been adopted by the 



































































telephone rather than in the clinic, deferral of non-urgent anticancer treatments, and 
shortening of radiotherapy fractionation schedules. he available evidence of efficacy(11–16) 
has been balanced against what we know of the risks from COVID-19. to form consensus 
guidance As more evidence of the true impact of COVID-19 on the UK population becomes 
available we will need to continue to review the guidelines to make the best use of the 
evidence we have to support safe practice and enable an informed discussion with our 
patients about the risks of treatment (17–20).  
Despite the increased difficulty of treating cancer patients at present, medical professionals 
from around the UK have shown themselves to be adaptable and resilient. This collaborative, 
cross-disciplinary approach has been hugely important in optimising the delivery of patient 
care, enabled by our ability to share information about our experiences. A core part of this 
going forward will be the UK Coronavirus Cancer Monitoring Project, which aims to monitor 
the impact of COVID-19 on cancer patients and enable oncologists to gain crucial insights 
and inform clinical- and infrastructure-based decision-making. 
The UK Coronavirus Cancer Monitoring Project (UKCCMP), was launched on 18th March 
2020 following discussions between clinical oncologists in our cancer centres. The project 
consists of a Local Emergency Response Reporting Group at each of our cancer centres 
and enables data collection on SARS-CoV-2-positive cancer patients. The primary endpoint 
measure of this study will be all-cause mortality following a hospitalization for a laboratory 
confirmed SARS-CoV-2 infection. The project will attempt to define factors that are 
associated with increased mortality/morbidity from COVID-19, including patient factors (age, 
sex, co-morbidities, smoking status, and ethnicity), cancer factors (subtype, stage), cancer 
treatment (intent, modality, line of treatment) and COVID-19 symptoms and treatments. 
To date, there are over a 1000 patients in the registry. Potentially of interest to the 
readership, is that there are 92 patients who have had radiotherapy within 4 weeks of 
admission. This subgroup is increasing in size and will hopefully enable the clinical oncology 
community to answer some of the aforementioned clinical questions given enough time and 
collaboration. Therefore, we believe this pan-UK information is key to understanding the 
interactions between COVID-19 and our treatment regimes.  
The project will continue to analyse and disseminate data in real time. This will enable our 
cancer centres to assess the impact coronavirus is having on cancer patients, assess the 
impact of our treatment interventions and potentially allow the maintenance of the best 
possible standard of cancer patient care within challenging circumstances. 
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